Yusuf Nasrullah is a scientist at Verve Therapeutics with a vital interest in therapeutic design, protein engineering and pathway biology. Prior to joining Verve Therapeutics, he worked at Neon Therapeutics as an immune-oncologist and previously served on the team at Organon Pharmaceuticals which fashioned the blockbuster anti-PD1 antibody Keytruda, now owned by Merck. He received his M.S. in biological sciences and his B.S. with First Class Honours in biochemistry from the University of Manchester in Great Britain.